Evidence map›Paper›PMID 41430239›Full record

ArticleCancer cell international2025

3,3'-Diindolylmethane blocks the dissemination of gastric cancer cells in the peritoneal cavity through the MFGE8-MAPK/ERK signaling pathway.

Jiaqing Liu, Yuzhe Zhang, Lirong Yan, Fang Li, Aoran Liu, Yi Yang, Chunjiao Yang, Yanke Li, Ye Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaqing Liu *The First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Yuzhe Zhang *The First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Lirong Yan *The First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Fang LiThe First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Aoran LiuThe First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China.
Yi YangDepartment of Laboratory Animal Science, China Medical University, Shenyang, China.
Chunjiao YangThe First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China. yangchunjiao@163.com.
Yanke LiDepartment of Anorectal Surgery, the First Hospital of China Medical University, Shenyang, China. liyanke1437@163.com.
Ye ZhangThe First Laboratory of Cancer Institute, the First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang City, 110001, China. zhangyecmu@163.com.

Funding

National Natural Science Foundation of China 82073244Shenyang Youth Science and Technology Innovation Talent Project RC200267
6 · The paper itself

Abstract

purposeMilk fat globule epidermal growth factor 8 (MFGE8) has been demonstrated to have the potential to facilitate the onset and advancement of different forms of cancer. Studies have shown that 3,3’-Diindolylmethane (DIM) has the ability to suppress GC. The precise function and operational mechanism of MFGE8 and DIM in relation to gastric cancer peritoneal dissemination (GCPD) remain poorly understood.

methodsThe role of MFGE8 in GC and GCPD was confirmed through the use of bioinformatics and patient tissues in this study. Malignant biological behavior and changes in protein expression were detected using CCK-8, colony formation, adhesion assay, transwell, and western blotting techniques. To assess the in vivo effects of MFGE8 and DIM, mice models were used.

resultsBased on our findings, MFGE8 could serve as a therapeutic target for GC and GCPD, while also stimulating the aggressive biological behavior of GC cells. DIM could be an effective inhibitor of the oncogenic properties of GC cells. Subsequent studies revealed that DIM was capable of inhibiting the activation of Mitogen-activated protein kinase (MAPK)/Extracellular signal-regulated kinase (ERK) signaling pathway by blocking MFGE8, leading to the ultimate suppression of GCPD by impeding the epithelial-mesenchymal transition procedure.

conclusionMFGE8 had the potential to be regarded as a marker that could provide prognostic information for GC and GCPD. Furthermore, MFGE8-MAPK/ERK pathway might be involved in the mechanism of DIM inhibiting GCPD.

Indexed as

DIMGastric cancerMAPK/ERKMFGE8Peritoneal dissemination

Identifiers

PMID41430239
PMCPMC12837949

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.